Amendments to the Claims
(Clean Version)

5. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of a heparin binding domain of fibroblast growth factor, and immunogenic fragments thereof; and

(b) a pharmaceutically acceptable carrier.

6. (Twice Amended) The composition of Claim 5, wherein the amino acid sequence of the immunogenic peptide consists of SEQ ID NOS: 1 or 2.

15. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments thereof

(b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; and

(c) a pharmaceutically acceptable carrier.

16. (Cancel) The composition of Claim 15, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

Sub D3

25. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor, wherein the immunogenic peptide fragment of fibroblast growth factor consists of a heparin binding domain and immunogenic fragments thereof, and wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of a receptor binding domain and immunogenic fragments thereof; and

(b) a pharmaceutically acceptable carrier.

ADD D4

Amendments to the Claims
(Marked Up Version)

Please amend the following claims by deleting the words in brackets and inserting the underlined words.

5. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of [the] a heparin binding domain of fibroblast growth factor, and immunogenic fragments thereof; and

(b) a pharmaceutically acceptable carrier.

6. (Twice Amended) The composition of Claim 5, wherein the amino acid sequence of the immunogenic peptide [comprises] consists of SEQ ID NOS: 1 or 2.

15. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of [the] a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments thereof[; and]

(b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9; and

(c) a pharmaceutically acceptable carrier.

16. (Cancel) The composition of Claim 15, wherein the amino acid sequence of the immunogenic peptide comprises SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.

25. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor, wherein the immunogenic peptide fragment of fibroblast growth factor consists of [the] a heparin binding domain and immunogenic fragments thereof, and wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of [the] a receptor binding domain and immunogenic fragments thereof; and

(b) a pharmaceutically acceptable carrier.

Pending Claims

Following entry this amendment, Claims 5-13, 15, 17-23, and 25-29 provided below will be pending in this application.

5. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of a heparin binding domain of fibroblast growth factor, and immunogenic fragments thereof; and

(b) a pharmaceutically acceptable carrier.

6. (Twice Amended) The composition of Claim 5, wherein the amino acid sequence of the immunogenic peptide consists of SEQ ID NOS: 1 or 2.

7. The composition of Claim 5, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

8. The composition of Claim 7, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

9. The composition of Claim 7, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

10. The composition of Claim 9, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed ß-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

11. The composition of Claim 5, further comprising a hydrophobic moiety attached to the immunogenic peptide.

12. The composition of Claim 11, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

13. The composition of Claim 11, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

17. The composition of Claim 15, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

18. The composition of Claim 17, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

19. The composition of Claim 17, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

20. The composition of Claim 19, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed ß-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

21. The composition of Claim 15, further comprising a hydrophobic moiety attached to the immunogenic peptide.

22. The composition of Claim 21, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

23. The composition of Claim 21, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

25. (Twice Amended) An immunogenic composition comprising,

(a) an immunogenic peptide fragment of fibroblast growth factor and vascular endothelial growth factor, wherein the immunogenic peptide fragment of fibroblast growth factor consists of a heparin binding domain and immunogenic fragments thereof, and wherein the immunogenic peptide fragment of vascular endothelial growth factor consists of a receptor binding domain and immunogenic fragments thereof; and

(b) a pharmaceutically acceptable carrier.

26. The composition of Claim 25, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

27. The composition of Claim 26, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole lympet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L-amino acids.

28. The composition of Claim 26, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

29. The composition of Claim 28, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed ß-(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.